Los Angeles, 9 July — A genetically modified herpes simplex virus, RP1, in combination with nivolumab, has shown the ability to shrink and even eliminate advanced melanoma tumors—including those not directly injected—in early clinical trials. This pioneering approach in oncolytic virotherapy offers hope for patients with treatment-resistant melanoma. In a phase 1/2 trial involving 140 patients […]